Evidence map›Paper›PMID 24850152›Full record

ArticleKidney international2014

Tissue-specific deletion of Crry from mouse proximal tubular epithelial cells increases susceptibility to renal ischemia-reperfusion injury.

Jing Miao, Allison M Lesher, Takashi Miwa, Sayaka Sato, Damodar Gullipalli, Wen-Chao Song

Abstract read
In one paragraph

Article in Kidney international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Dual role of complement in neuronal repair.Frontiers in immunology · 2025
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Jing MiaoDepartment of Pharmacology and Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Allison M LesherDepartment of Pharmacology and Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Takashi MiwaDepartment of Pharmacology and Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Sayaka SatoDepartment of Pharmacology and Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Damodar GullipalliDepartment of Pharmacology and Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Wen-Chao SongDepartment of Pharmacology and Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Funding

BIOLOGY OF DECAY ACCELERATING FACTORR01AI044970 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SONG, WENCHAO · 2000 to 2014
$4.9M
Pathogenesis and therapy of dense deposit disease in a mouse modelR01AI085596 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SONG, WENCHAO · 2010 to 2019
$3.5M
Complement Regulatory Proteins and Autoimmune DiseaseR01AI049344 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SONG, WENCHAO · 2002 to 2011
$3.3M
Mechanism of protection of DAF and CD59 in SLER01AI063288 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SONG, WENCHAO · 2005 to 2009
$1.9M
Regulation of Toll-like receptor signaling by complementR01GM092108 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI SONG, WENCHAO · 2009 to 2012
$1.3M
Complement Regulatory Proteins and Autoimmune DiseaseR21AI049344 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI SONG, WENCHAO · 2001 to 2001
$302k
NIAID NIH HHS AI044970NIAID NIH HHS AI049344NIAID NIH HHS AI085596NIAID NIH HHS R01 AI044970NIAID NIH HHS R01 AI049344NIAID NIH HHS R01 AI063288NIAID NIH HHS R01 AI085596NIAID NIH HHS R21 AI049344NIGMS NIH HHS GM092108NIGMS NIH HHS R01 GM092108
6 · The paper itself

Abstract

The murine cell surface protein Crry (complement receptor 1-related protein/gene y) is a key complement regulator with similar activities to human membrane cofactor protein (MCP) and decay-accelerating factor. MCP has a critical role in preventing complement-mediated tissue injury and its mutation has been implicated in several human kidney diseases. The study of Crry in mice has relevance to understanding MCP activity in human diseases; however, such efforts have been hampered by the embryonic lethality phenotype of Crry gene knockout. Here we used a conditional gene-targeting approach and deleted Crry from the mouse proximal tubular epithelial cells where Crry is prominently expressed. Absence of Crry from proximal tubular epithelial cells resulted in spontaneous C3 deposition on the basolateral surface but no apparent renal disease in unchallenged mice. However, mice deficient in Crry on proximal tubular epithelial cells developed exacerbated renal injury when subjected to renal ischemia-reperfusion, showing increased blood urea nitrogen levels, higher tubular injury scores, more tubular epithelial cell apoptosis, and inflammatory infiltrates. Renal ischemia-reperfusion injury in the Crry conditional knockout mice was prevented by blocking C3 and C5 activation using an anti-properdin or anti-C5 monoclonal antibody (mAb), respectively. Thus, Crry has a critical role in protecting proximal tubular epithelial cells during ischemia-reperfusion challenge. Our results highlight the latent risk for inflammatory kidney injury associated with defects in membrane complement regulators.

Indexed as

Genetic Predisposition to DiseaseAnimalsAntibodies, MonoclonalApoptosisBlood Urea NitrogenComplement ActivationComplement C3Complement C5Epithelial CellsGene Knockout TechniquesKidney Tubules, ProximalMiceMice, KnockoutPhagocytesProperdinReceptors, ComplementAntibodies, MonoclonalComplement C3Complement C5Cr1l protein, mouseProperdinReceptors, ComplementReceptors, Complement 3b

Identifiers

PMID24850152
PMCPMC4182132

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.